Try a new search

Format these results:

Searched for:

in-biosketch:true

person:caplaa02

Total Results:

92


New and Emerging Dermatophytes

Quan, Irene; Kasarskis, Irina M; Williams, Andrew S; Mueller, Kyle; Quilter, Laura A S; Trinidad, John L; Ellen Freeman, Esther; Zucker, Jason; Gold, Jeremy A W; Caplan, Avrom S
Emerging dermatophytes, particularly Trichophyton indotineae and Trichophyton mentagrophytes genotype VII (TMVII), are reshaping the epidemiology of dermatophytosis through increasing treatment-refractory disease and transmission via skin-to-skin contact, including intimate or sexual contact. This article summarizes the epidemiology, clinical presentation, diagnosis, and management of these pathogens, with emphasis on distinguishing features relevant to clinical practice and a brief overview of emerging treatment resistance in Trichophyton rubrum. We also discuss diagnostic limitations, antifungal stewardship, infection prevention, and surveillance gaps. Increased clinician awareness and expanded access to molecular diagnostics are critical to improving outcomes and limiting transmission.
PMID: 43025931
ISSN: 1558-0520
CID: 6075931

Mycetoma in the United States: A Clinical Review

Barnawi, Ghassan; Lazarowitz, Raquel; Caplan, Avrom S; Cox, Victoria R V; Elewski, Boni; Pappas, Peter G; Smith, Dallas J; Lipner, Shari R
Mycetoma is a neglected chronic granulomatous infection of the skin and subcutaneous tissue caused by filamentous bacteria (actinomycetoma) or fungi (eumycetoma). Although classically associated with tropical and subtropical regions, cases have been reported in the United States and the disease is underrecognized, leading to misdiagnosis and delayed treatment. This clinical review synthesizes United States-focused evidence on mycetoma epidemiology, risk factors, clinical presentation, diagnostic evaluation, and management. In the United States, mycetoma may be acquired abroad or locally, particularly in warmer regions, and reported demographic patterns differ from endemic areas, with cases often affecting older and urban populations. Clinically, it usually presents as a slowly progressive, painless subcutaneous nodule with draining sinuses and grain-containing discharge. Accurate distinction between actinomycetoma and eumycetoma is essential for appropriate treatment. Diagnosis relies on early collection of grains and deep tissue for histopathology and culture, with bedside microscopy as an adjunct, and imaging to define disease extent and bone involvement. Actinomycetoma is managed with prolonged antibiotics and is often cured without surgery, whereas eumycetoma typically requires long-term antifungal therapy plus surgical excision, with higher recurrence risk and rates of amputation.
PMID: 43003271
ISSN: 1097-6787
CID: 6075744

Clinical Characteristics, Etiologic Associations, and Treatment Outcomes of Pernio

Martins, Kaitlin; Ristianto, Zasca-Aisha; Manduca, Sophia; Scandurro, Camille; Martin, Mackenzie R; Mazori, Daniel R; Caplan, Avrom S; Femia, Alisa N
PMCID:13756197
PMID: 43013286
ISSN: 2168-6084
CID: 6075813

Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial

Rosenbach, Misha; Shields, Bridget E; Coates, Margaret; Obi, Ogugua Ndili; Marano, Anne L; Mangold, Aaron R; Onajin, Oluwakemi; Haemel, Anna; Fivenson, David; Culver, Daniel A; Judson, Marc A; Hannah, Claire; Smuda, Craig; Polly, Samantha; Unwala, Rashmi; Harper, Logan; Neto, Manuel L Ribeiro; James, W Ennis; Vakharia, Paras; Nguyen, Cuong V; Foulke, Galen; Al-Awqati, Mina; Helm, Matthew; Hsu, Sylvia; Gupta, Rohit; Culton, Donna A; Pariser, Robert; Talia, Jordan; Baker, Matthew C; Shaw, Katharina S; Johnson, Brendan; Cascino, Matthew D; Mandell, Brian; Sweiss, Nadera; Graham, Lauren; Barney, Joseph; Imadojemu, Sotonye; Caplan, Avrom S; Damsky, William
IMPORTANCE/UNASSIGNED:Cutaneous sarcoidosis (CS) is a chronic granulomatous skin disease associated with substantial morbidity and no approved therapies. OBJECTIVE/UNASSIGNED:To evaluate the efficacy and safety of brepocitinib, an oral, selective, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with CS. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:BEACON is an ongoing, global, multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial. This prespecified interim analysis evaluated the 16-week, dose-ranging phase 2 portion of the study conducted between April 9, 2025, and July 18, 2025. Adults with biopsy-proven active CS were randomized 3:2:2 to receive brepocitinib, 45 mg; brepocitinib, 15 mg; or placebo once daily. MAIN OUTCOMES AND MEASURES/UNASSIGNED:The primary efficacy outcome was change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at week 16. Additional outcomes included achievement of Cutaneous Sarcoidosis Activity-Investigator Global Assessment (CSA-IGA) clear or almost clear with a 2 or greater category improvement, CSAMI-A response (≥50% relative improvement), 10-point or greater CSAMI-A score reduction, achievement of a CSAMI-A score less than 5, patient-reported outcomes, and safety. RESULTS/UNASSIGNED:Thirty-one participants (mean [SD] age, 53.3 [9.6] years; 18 female individuals [58%] and 13 male individuals [42%]) were enrolled. Both brepocitinib doses achieved rapid, significant improvements in CS disease activity: by week 16, CSAMI-A scores improved by 22.3 points in the 45-mg group and 22.2 points in the 15-mg group compared with a 0.7-point improvement with placebo (P < .001). Across increasingly stringent responder-based and cutaneous remission-oriented end points, efficacy consistently favored brepocitinib, 45 mg, supporting a dose-dependent treatment effect. Compared with placebo, brepocitinib, 45 mg, resulted in higher rates of CSA-IGA clear or almost clear disease (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reduction (100% vs 14.3%; P < .001), and achievement of a CSAMI-A score of less than 5 (61.5% vs 0%; P = .005). Clinical benefit extended to difficult to treat phenotypes, including lupus pernio, despite protocol-mandated systemic glucocorticoid discontinuation, and was accompanied by substantial improvements in skin-related quality of life. No deaths or serious adverse events occurred. CONCLUSIONS AND RELEVANCE/UNASSIGNED:In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 evaluation. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT06978725.
PMCID:13752788
PMID: 43008126
ISSN: 2168-6084
CID: 6075780

Impact of phosphodiesterase-5 inhibitor treatment delay on secondary Raynaud's phenomenon outcomes: A retrospective cohort study

Zappi, Isabella; Maas, Derek; Sikora, Michelle; Spindler, Archie; Nohria, Ambika; Desai, Deesha D; Obijiofor, Chinemelum; Richardson, William Mark; Shapiro, Jerry; Femia, Alisa N; Saxena, Amit; Caplan, Avrom S; Mazori, Daniel R; Lo Sicco, Kristen I
PMID: 42190748
ISSN: 1097-6787
CID: 6075538

Cutaneous Polyarteritis Nodosa Has Prolonged Diagnostic Delays and Frequent Overlap with Systemic Disease

Manduca, Sophia; Martin, Mackenzie R; Ristianto, Zasca-Aisha; Martins, Kaitlin; Mandal, Soutrik; Mazori, Daniel R; Caplan, Avrom S; Femia, Alisa N
PMID: 42933664
ISSN: 1097-6787
CID: 6074729

Oral Minoxidil for Alopecia in Systemic Sclerosis, Dermatomyositis, Mixed Connective Tissue Disease, and Undifferentiated Connective Tissue Disease: A Retrospective Chart Review on Cardiovascular Risk

Zappi, Isabella; Spindler, Archie; Maas, Derek; Zaminski, Devyn; Sharp, Kelley; Lakdawala, Nikita R; Oza, Vikash S; Orlow, Seth J; Shapiro, Jerry; Caplan, Avrom S; Femia, Alisa N; Lo Sicco, Kristen I; Mazori, Daniel R
PMID: 42849748
ISSN: 1097-6787
CID: 6074024

Consensus recommendations for Trichophyton indotineae: A modified Delphi study

Gupta, Aditya K; Talukder, Mesbah; Saunte, Ditte Marie L; Hay, Roderick James; Arabatzis, Michael; Caplan, Avrom S; Galili, Eran; Haneke, Eckart; Iorizzo, Matilde; Kassem, Riad; Khurana, Ananta; Lipner, Shari R; Lyakhovitsky, Anna; Morrison, Brian W; Piguet, Vincent; Piraccini, Bianca Maria; Rodríguez-Cerdeira, Carmen; Shemer, Avner; Starace, Michela; Sundnes, Olav; Tosti, Antonella
BACKGROUND:Trichophyton indotineae (T. mentagrophytes genotype VIII) is spreading globally and is often terbinafine resistant. Guidance for diagnosis and treatment remains inconsistent. METHODS:We performed a four-round modified Delphi study. A steering group developed a literature-informed, 42-item questionnaire on diagnosis and management. Consensus was predefined as ≥70% agreement. RESULTS:Thirty-four experts were invited; 20 completed rounds 1 and 2 and 19 completed rounds 3 and 4. Consensus was achieved for 34/42 items (80.95%). The panel advised suspecting T. indotineae infection in patients with extensive or terbinafine-recalcitrant dermatophytosis, particularly those with a history of travel to or residence in endemic regions. For diagnosis, the panel recommended KOH direct microscopy and fungal culture for suspected dermatophyte infection, and PCR (polymerase chain reaction) with species-level discrimination or ITS sequencing for confirmation of T. indotineae. For resistance assessment, SQLE sequencing and antifungal susceptibility testing were preferred where available, particularly after treatment failure. For treating superficial fungal infections caused by T. indotineae, experts recommended oral itraconazole therapy (100-200 mg/day for 6-8 weeks, or longer as clinically indicated), with luliconazole 1% cream as the preferred adjunctive topical option. Oral posaconazole (300 mg/day for 4-12 weeks) can be considered as the salvage therapy following itraconazole failure, keeping in mind antifungal stewardship. CONCLUSIONS:These consensus statements provide practical interim recommendations. Randomized controlled trials are needed to validate outcomes and optimize regimens.
PMID: 42786909
ISSN: 1468-3083
CID: 6073576

A new era of dermatophytes: emerging species, new risk factors, and taxonomic change

Summerbell, Richard C; Caplan, Avrom S; Cox, Victoria R V; Scott, James A; Kidd, Sarah E
SUMMARYThe traditional landscape of dermatophyte infections has changed over the past decade. The emergence and global expansion of Trichophyton indotineae have highlighted the impact of irrational and uncontrolled antifungal and topical corticosteroid use, presented treatment challenges, and highlighted the deficiencies of currently available diagnostic methods. Trichophyton mentagrophytes genotype VII, which has until recently been associated with animal reservoirs, is now associated with human-to-human transmission and is frequently related to sexual transmission. Infections associated with emerging dermatophytes are notable for atypical presentations that may include widespread, inflamed lesions, terbinafine resistance, and frequent relapse. The classic presentation of tinea lesions is frequently obscured by the application of topical corticosteroids, leading to delays in clinical recognition, diagnosis, and appropriate treatment, perpetuating further misuse of topical medications. Deep or invasive dermatophytoses, including Majocchi's granuloma, may occur in immunocompromised patients. The introduction of matrix-assisted laser desorption/ionization-time of flight mass spectrometry and molecular detection of dermatophytes has improved the diagnostic landscape for dermatophytes. However, currently, most assays do not specifically detect T. indotineae or T. mentagrophytes genotype VII, hindering the diagnosis and surveillance. Sequencing of the internal transcribed spacer (ITS) region is required for definitive identification. Terbinafine and azole resistance is common in T. indotineae and increasingly being reported for other species. While nomenclatural changes have been introduced and debated over many decades, the last decade has seen the introduction of new genera, e.g., Nannizzia, Paraphyton, and Lophophyton. An overview of currently recognized dermatophyte species, complexes, and genera is presented here, describing phylogenetic, ecological, and biochemical relatedness. The ethical conundrum of the name Trichophyton indotineae is also discussed.
PMID: 42725743
ISSN: 1098-6618
CID: 6072270

Rethinking Antifungal Therapy in Seborrheic Dermatitis

Barbieri, John S; Berna, Ronald; Caplan, Avrom S
PMID: 42616546
ISSN: 2168-6084
CID: 6071474